Study of Rituximab Treatment for Long-Term Remission in Adults With Chronic Inflammatory Demyelinating Polyneuropathy CIDP

What this Trial Is About

Researchers are studying whether the drug rituximab can cause remission in patients with chronic inflammatory demyelinating polyneuropathy CIDP. The trial includes two groups newly diagnosed patients starting standard immunoglobulin treatment and patients already dependent on immunoglobulin therapy. The goal is to assess the effectiveness of rituximab, including its use after relapse following previous rituximab treatment, to potentially reduce the need for ongoing immunoglobulin therapy. All participants will receive rituximab infusions twice at the start and once more at six months. Newly diagnosed patients will also receive immunoglobulin infusions every three weeks for the first three to six months, while patients already on immunoglobulin will continue their regular therapy before it is gradually reduced and stopped between months three and six. Rituximab will be given intravenously in a hospital setting. Participants will be followed for two years with about 10 clinic visits for checkups, questionnaires, and blood draws. Researchers will measure remission at 52 weeks, defined by improvement or stable disability without the need for further treatment. Safety and other outcomes like pain, fatigue, quality of life, and adverse events will also be monitored throughout the study period.

Rituximab Induced Remission in Patients With Chronic Inflammatory Demyelinating Polyneuropathy